Fortrea Holdings is a contract research organization providing phase I through IV biopharmaceutical product and medical device services, patient access solutions and other services. Co. provides its pharmaceutical, biotechnology, and medical device customers with clinical pharmacology, clinical development, and other service capabilities. Co. manages its business in two segments: Clinical Services, which brings solutions to market which include clinical pharmacology and clinical development capabilities; as well as Enabling Services, which provides patient access and technology solutions which can be deployed across any of its global solutions depending on the scope of its customers' needs.
When researching a stock like Fortrea Holdings, many investors are the most familiar with Fundamental Analysis — looking at a company's balance sheet, earnings, revenues, and what's happening in that company's underlying business. Investors who use Fundamental Analysis to identify good stocks to buy or sell can also benefit from FTRE Technical Analysis to help find a good entry or exit point. Technical Analysis is blind to the fundamentals and looks only at the trading data for FTRE stock — the real life supply and demand for the stock over time — and examines that data in different ways. One of these ways is called the Relative Strength Index, or RSI. This popular indicator, originally developed in the 1970's by J. Welles Wilder, looks at a 14-day moving average of a stock's gains on its up days, versus its losses on its down days. The resulting FTRE RSI is a value that measures momentum, oscillating between "oversold" and "overbought" on a scale of zero to 100. A reading below 30 is viewed to be oversold, which a bullish investor could look to as a sign that the selling is in the process of exhausting itself, and look for entry point opportunities. A reading above 70 is viewed to be overbought, which could indicate that a rally in progress is starting to get crowded with buyers. If the rally has been a long one, that could be a sign that a pullback is overdue. |